Financial News
Articles published by Janux Therapeutics, Inc.
Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference
February 14, 2023
Via Business Wire
Tickers
JANX
Via Business Wire
Tickers
JANX
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 10, 2022
Via Business Wire
Tickers
JANX
Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources
September 23, 2022
Via Business Wire
Tickers
JANX
Janux Therapeutics Appoints Winston Kung to Board of Directors
September 22, 2022
Via Business Wire
Tickers
JANX
Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September
August 31, 2022
Via Business Wire
Tickers
JANX
Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 09, 2022
Via Business Wire
Tickers
JANX
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
May 10, 2022
Via Business Wire
Tickers
JANX
Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference
January 05, 2022
Via Business Wire
Tickers
JANX
Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results
November 09, 2021
Via Business Wire
Tickers
JANX
Janux Therapeutics to Present Virtually at Upcoming Investor Conferences
November 08, 2021
Via Business Wire
Tickers
JANX
Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors
September 09, 2021
Via Business Wire
Tickers
JANX
Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference
September 07, 2021
Via Business Wire
Tickers
JANX
Janux Therapeutics Reports Second Quarter 2021 Financial Results
August 10, 2021
Via Business Wire
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.